Compare SY & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | PEPG |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 289.0M | 317.6M |
| IPO Year | 2019 | 2022 |
| Metric | SY | PEPG |
|---|---|---|
| Price | $2.91 | $5.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $5.50 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 786.7K | 737.8K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,132,009.00 | N/A |
| Revenue This Year | $5.27 | N/A |
| Revenue Next Year | $51.30 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.67 | $0.88 |
| 52 Week High | $6.28 | $6.72 |
| Indicator | SY | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 42.74 | 51.13 |
| Support Level | $2.78 | $5.08 |
| Resistance Level | $3.00 | $6.72 |
| Average True Range (ATR) | 0.17 | 0.43 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 23.64 | 42.11 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.